NCT00304616

SWitching to Abilify Trial (SWAT)

A Multi-center, Randomized, Open, Treatment-switching Study From Orally Administered Antipsychotic Monotherapy in the Treatment of Chronic Schizophrenic and Schizoaffective Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 500 (planned)
• Sponsor: Korea Otsuka Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy, safety and tolerance of an 12 and 26-week aripiprazole administration

Detailed description

This trial was designed to evaluate the efficacy, safety and tolerance of an 12 and 26-week aripiprazole administration to schizophrenic outpatients who maintain stable (no change with dosage, usage, route of the most recent antipsychotic drugs) symptoms and discontinued previous antipsychotic drugs. Aripiprazole (10\~30 mg/day) will be orally administered for 12 weeks followed by an extension phase for a maximum of an additional 14 weeks (total of 26 weeks).

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone

Timeline

• Start date: 2004-10-01
• Primary completion: 2006-06-01
• Completion: 2007-10-01
• First posted: 2006-03-20
• Last updated: 2009-12-17

Locations

1 site across 1 country: South Korea